FACTORS ASSOCIATED WITH LONG-TERM DAMAGE IN THE ANCA-ASSOCIATED VASCULITIDES: AN ANALYSIS OF COHORTS FROM THE EUROPEAN VASCULITIS STUDY GROUP THERAPEUTIC TRIALS

FACTORS ASSOCIATED WITH LONG-TERM DAMAGE IN THE ANCA-ASSOCIATED VASCULITIDES: AN ANALYSIS OF COHORTS FROM THE EUROPEAN VASCULITIS STUDY GROUP THERAPEUTIC TRIALS

Bibliographic Details
Main Authors:	Robson, J, Doll, H, Yew, S, Flossmann, O, Suppiah, R, Harper, L, Hoglund, P, Jayne, D, Mukhtyar, C, Westman, K, Luqmani, R
Format:	Conference item
Published:	2013

Similar Items

TREATMENT-RELATED DAMAGE IN THE ANCA-ASSOCIATED VASCULITIDES: AN ANALYSIS OF THE EUROPEAN VASCULITIS STUDY GROUP THERAPEUTIC TRIALS
by: Robson, J, et al.
Published: (2013)

Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials.
by: Robson, J, et al.
Published: (2015)

Damage in the ANCA-associated vasculitides: Long-term data from the European Vasculitis Study Group (EUVAS) therapeutic trials
by: Robson, J, et al.
Published: (2015)

THE PROGNOSTIC VALUE OF THE BIRMINGHAM VASCULITIS ACTIVITY SCORE AND THE VASCULITIS DAMAGE INDEX IN ANCA-ASSOCIATED VASCULITIS
by: Suppiah, R, et al.
Published: (2011)

Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials.
by: Robson, J, et al.
Published: (2014)

Glucocorticoid Treatment and Damage In The Antineutrophil- Cytoplasm Antibody Associated Vasculitides
by: Robson, J, et al.
Published: (2013)

Cardiovascular outcomes in ANCA associated vasculitis
by: Mukhtyar, C, et al.
Published: (2008)

THE DISEASE CHARACTERISTICS OF ANCA ASSOCIATED VASCULITIS: 735 PATIENTS RECRUITED AT DIAGNOSIS TO SIX EUROPEAN VASCULITIS STUDY GROUP TRIALS
by: Yew, S, et al.
Published: (2012)

Long-term survival of ANCA-associated vasculitis
by: Flossmann, O, et al.
Published: (2009)

Treatment related damage in the ANCA-associated vasculitides: An analysis of cohorts from the European Vasculitis Study Group (EUVAS) therapeutic trials
by: Robson, J, et al.
Published: (2013)

THE DEMOGRAPHY OF ANCA ASSOCIATED VASCULITIS: 735 PATIENTS RECRUITED AT DIAGNOSIS TO SIX EUROPEAN VASCULITIS STUDY GROUP TRIALS
by: Yew, S, et al.
Published: (2012)

Classification criteria for the anca-associated vasculitides
by: Robson, J, et al.
Published: (2019)

Long-term patient survival in ANCA-associated vasculitis.
by: Flossmann, O, et al.
Published: (2011)

Long-term patient survival in ANCA-associated vasculitis
by: Flossmann, O, et al.
Published: (2011)

Outcome measures in ANCA-associated vasculitis.
by: Suppiah, R, et al.
Published: (2010)

Long-term patient survival in ANCA-associated vasculitis.
by: Flossmann, O, et al.
Published: (2011)

Factors associated with long-term damage in the ANCA-associated vasculitides: An analysis of cohorts from the European vasculitis study group (EUVAS) therapeutic trials
by: Robson, J, et al.
Published: (2013)

Towards diagnostic criteria for the ANCA-associated vasculitides.
by: Luqmani, R
Published: (2007)

Damage assessment in ANCA-associated vasculitis.
by: Bhamra, K, et al.
Published: (2012)

Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials.
by: Suppiah, R, et al.
Published: (2011)

Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials
by: Suppiah, R, et al.
Published: (2011)

Explaining fatigue in ANCA-associated vasculitis
by: Basu, N, et al.
Published: (2013)

Explaining fatigue in ANCA-associated vasculitis.
by: Basu, N, et al.
Published: (2013)

EULAR recommendations for conducting clinical studies and/or clinical trials in ANCA-associated vasculitis
by: Luqmani, R, et al.
Published: (2007)

Clinical and biological assessment in systemic necrotizing vasculitides.
by: Mukhtyar, C, et al.
Published: (2006)

Markers for work disability in ANCA-associated vasculitis
by: Basu, N, et al.
Published: (2013)

The prognostic value of BVAS and VDI in ANCA-AAV
by: Suppiah, R, et al.
Published: (2011)

Diagnosis and management of ANCA associated vasculitis.
by: Berden, A, et al.
Published: (2012)

Prevalence and associations of peripheral neuropathy at disease-onset in ANCA-associated vasculitides: Data from DCVAS study
by: Michael, C, et al.
Published: (2018)

The characterisation and determinants of quality of life in ANCA associated vasculitis
by: Basu, N, et al.
Published: (2014)

CONTEXTUALISING QUALITY OF LIFE IN ANCA ASSOCIATED VASCULITIS (AAV)
by: Basu, N, et al.
Published: (2012)

The characterisation and determinants of quality of life in ANCA associated vasculitis.
by: Basu, N, et al.
Published: (2014)

Atherosclerosis in ANCA-associated systemic vasculitides
by: E I Kuznetsova, et al.
Published: (2012-06-01)

Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis.
by: Mukhtyar, C, et al.
Published: (2006)

Maintenance of clinical remission in ANCA-associated vasculitis.
by: Luqmani, R
Published: (2013)

THU0306 Prevalence and characteristics of neuropathy in patients with ANCA associated vasculitides: data from the DCVAS study
by: Bischof, A, et al.
Published: (2017)

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
by: Jones, R, et al.
Published: (2010)

Determinants of Poor Quality of Life in ANCA Associated Vasculitis (AAV).
by: Basu, N, et al.
Published: (2012)

EULAR/ERA-EDTA RECOMMENDATIONS FOR THE MANAGEMENT OF ANCA-ASSOCIATED VASCULITIS
by: Yates, M, et al.
Published: (2016)

Cutaneous manifestations of ANCA-associated vasculitis
by: Chiesafuxench, Z, et al.
Published: (2016)